Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation & Amortization (CF) (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $65000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 14.47% to $65000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Dec 2025, down 10.71% year-over-year, with the annual reading at $300000.0 for FY2025, 10.71% down from the prior year.
  • Depreciation & Amortization (CF) hit $65000.0 in Q4 2025 for Silence Therapeutics, down from $81000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $88000.0 in Q1 2024 to a low of $65000.0 in Q4 2025.